A randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of anagliptin in drug-naïve patients with type 2 diabetes
Year: 2015
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: The aim of this study was to evaluate the efficacy and safety of anagliptin in drug-naïve patients with type 2 diabetes in a double-blind randomized placebo-controlled study. A total of 109 patients were randomized to 100 mg (n=37) or 200 mg (n=33) anagliptin twice daily or placebo (n=39). The primary objective was to alter HbA1c levels from baseline at a 24-week endpoint. The overall baseline mean age and body mass index were 56.20 ± 9.77 years and 25.01 ± 2.97 kg/m(2), respectively, and the HbA1c level was of 7.14 ± 0.69 %. Anagliptin at 100 mg and 200 mg produced significant reductions in HbA1c (-0.50 ± 0.45 % and -0.51 ± 0.55%, respectively), and the placebo treatment resulted in an increase in HbA1c by 0.23 ± 0.62 %. Both doses of anagliptin produced significant decreases in fasting plasma glucose (-0.53 ± 1.25 mmol/L and -0.72 ± 1.25 mmol/L, respectively) and the proinsulin/insulin ratio (-0.04 ± 0.15 and -0.07 ± 0.18, respectively) compared with placebo. No meaningful body weight changes from baseline were observed in three groups. Plasma dipeptidyl peptidase (DPP)-4 activity was significantly inhibited after 24 weeks of anagliptin treatment, and >75% and >90% inhibitions were observed during the meal tolerance tests with 100 mg and 200 mg anagliptin, respectively. The incidences of adverse or serious adverse events were similar among the three study groups. Twice-daily anagliptin therapy effectively inhibited DPP-4 activity and improved glycemic control and was well-tolerated in patients with type 2 diabetes.
Source: Endocrine Journal
Authors: Hae Kyung Yang, Kyung Wan Min, Sung Woo Park, Choon Hee Chung, Kyong Soo Park, Sung Hee Choi, Ki-Ho Song, Doo-Man Kim, Moon-Kyu Lee, Yeon-Ah Sung, Sei Hyun Baik, In Joo Kim, Bong-Soo Cha, Jeong Hyun Park, Yu Bae Ahn, In-Kyu Lee, Soon Jib Yoo, Jaetaek Kim, Ie Byung Park, Tae Sun Park, Kun-Ho Yoon
Institutions: The Catholic University of Korea Seoul St. Mary's Hospital, Catholic University of Korea, Eulji University, Eulji Medical Center, Kangbuk Samsung Hospital, Sungkyunkwan University, Yonsei University, Seoul National University, Seoul National University Hospital, Seoul National University Bundang Hospital, The Catholic University of Korea Yeouido St. Mary's Hospital, Hallym University, Kangdong Sacred Heart Hospital, Samsung Medical Center, Ewha Womans University, Ewha Womans University Medical Center, Korea University, Pusan National University Hospital, Pusan National University, Yonsei University Health System, Inje University, Inje University Busan Paik Hospital, The Catholic University of Korea St. Vincent's Hospital, Kyungpook National University, The Catholic University of Korea Bucheon St. Mary's Hospital, Chung-Ang University, Gachon University Gil Medical Center, Jeonbuk National University Hospital, Jeonbuk National University
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2032089792
